USMA - DNCB References

DNCB References

[1] N. Wedroff. Zur frage der dinitrochlorbenzol-dermatosen. Arch. Derm, Syph. 154 (1928) 143-145.

[2] N.S. Wedroff, A.P. Dolgoff. Uber die specifische sensibilitat der haut enfachen chemischen stollen gegenuber. Arch. Derm. Syph. 171 (1935) 641-646.

[3] D. Landsteiner, M.W. Chase. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc. Soc. Exp. Biol. Med. 49 (1942) 688-690.

[4] M. Sulzberger, A. Rostenberg. Acquired specific supersensitivity to simple chemicals. J Immunol. 36 (1939) 17-27.

[5] W.L. Epstein, A.M. Kligman. The interference phenomenon in allergic contact dermatitis. J Invest Dermatol. 31 (1958) 103-106.

[6] W.J. Catalano, P.T. Taylor, A.S. Rabson, P.B. Chretien. A method of dinitrochlorobenzene contact sensitization. New Engl. J Med. 286 (1972) 399-402.

[7] R.B. Stricker, B.F. Elswood, D.I. Abrams. Dendritic cells and dinitrochlorobenzene (DNCB): A new treatment approach to AIDS. Immunol. Lett. 29 (1991) 191-196.

[8] R.B. Stricker, B. Goldberg, and W.L. Epstein. Topical immune modulation (TIM): a novel approach to the immunotherapy of systemic disease. Immunol. Lett. 59 (1997) 145-150.

[9] L.B. Mills. Stimulation of T-cellular immunity by cutaneous application of dinitrochlorobenzene. J. Am. Acad Dermatol. 14 (1986) 1089-1090.

[10] R.B. Stricker, Y.S. Zhu, B.F. Ellswood, C. Dumlao, J. Van Elk, T.G. Berger, J. Tappero, W.L Epstein, D.D. Kiprov. Pilot study of topical dinitrochlorobenzene (DNCB) in human immunodeficinency virus infection. Immunol. Lett. 36 (1993) 1-6.

[11] C.E. Mackewicz, H.W. Ortega, J.A. Levy. CD8 + cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Invest. 87 (1991) 1462-1466.

[12] S. Rowland-Jones, A. McMichael. Cytotoxic T lymphocytes in HIV infection. Semin. Virol. 4 (1993) 83-94.

[13] R.B. Stricker, B.F. Elswood, B. Goldberg, C. Dumlao, J. Van Elk, J. Henry, EE. Winger, W.L. Epstein. Clinical and immunologic evaluation of HIV-infected patients treated with dinitrochlorobenzene (DNCB). J. Am. Acad. Dermatol. 31 (1994) 462-466.

[14] A. Traub, S.B. Margolis, R.B. Stricker. Topical immune modulation with dinitrochlorobenzene in HIV disease: A controlled trial from Brazil. Dermatology 195 (1997) 369-373.

[15] R.B. Stricker, B. Goldberg, L.B. Mills, W.L. Epstein. Decrease in viral load associated with topical dinitrochlorobenzene therapy in HIV disease. Res. Virol. 148 (1997) 343-348.

[16] L.B. Mills, R.I. Frankel, E. Winger, W.L. Epstein. A controlled clinical trial of epicutaneous 1-chloro-2,4-dinitrochlorobenzetie (DNCB) patch in HIV infection. FDA IND application (1996), 2-10.

[17] P.D. Cruz, Jr. A controlled clinical trial of DNCB together with antiretrovirals as a treatment for HIV disease. NIH Grant application (1996), 80-82.

[18] R. Happle. The potential hazards of dinitrochlorobenzene. Arch. Dermatol. 121 (1985) 330-332.

[19] W.G. Dunagin. Potential hazards of dinitrochlorobenzene disputed. Arch. Dermatol. 122 (1986) 11-15.

[20] C.A.M. Reitmeijer, D.L. Cohn. Severe allergic contact dermatitis from
dinitrochlorobenzene. J Am. Acad Dermatol. 14 (1986) 490-491.

[21] S.E. Macatonia, R. Lau, S. Patterson, A.J. Pinching, S.C. Knight. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 71 (1990) 38-45.

[22] S.C. Knight, S.E. Macatonia, S. Patterson. Infection of dendritic cells with HIV 1: Virus load regulates stimulation and suppression of T-cell activity. Res. Virol. 144 (1993) 75-80.

[23] S. Patterson, M.S. Roberts, N.R. English, S.E. Macatonia, M.N. Gompels, A. J. Pinching, S.C. Knight. Detection of HIV DNA in peripheral blood dendritic cells of HIV-
infected individuals. Res. Virol. 145 (1994) 171-176.

[24] R.J. Dearman, I. Kimber. Differential stimulation of immune function by respiratory and contact chemical allergens. Immunology 72 (1991) 563-570.

[25] M. Cumberbatch, S.J. Gould, S.W. Peters, D.A. Basketter, R.J. Dearman, I. Kimber. Langerhans cells, antigen presentation, and the diversity of responses to chemical allergens. J Invest. Dermatol. 99 (1992) 107s-108s.

[26] M. Clerici, G.M. Shearer. A Thl-Th2 switch as a critical step in the etiology of HIV infection. Immunol. Today 14 (1993) 107-1 1 1.

[27] S. Romagnani, E. Maggi, G. Del Prete. An alternative view of the Thl/Th2 switch hypothesis in HIV infection. AIDS Res. Hum. Retroviruses 10 (I 994) iii-ix.

[28] S. Schrum, P. Probst, B. Fleischer, P.F. Zipfel. Synthesis of the CC-chemokines MIP-1-alpha, MIP-1-beta, and RANTES is associated with a type 1 immune response. J Immunol 157(8) (1996) 3598-3604.

[29] L. Wagner, 0.0 Yang, E.A. Garcia-Zepeda, Y. Ge, S.A. Kalams, B.D. Walker, M.S. Pastemack, A.D. Luster. Beta chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391 (1998) 908.

[30] P.A. Volberding, S.G. Deeks. Antiretroviral therapy for HIV infection. Promises and problems. JAMA 279 (1998) 1343-1344.

[31] R.B. Stricker, B. Goldberg. The Maginot line and AIDS vaccines. Med. Hypotheses 48 (1997) 527-529.

AIDS Clinic Menu:
"It's the Cheap Stuff, Stupid!" DNCB Background How DNCB Works How to Apply DNCB DNCB vs Conventional Treatments Side Effects of DNCB	DNCB Clinical Trials Summary References Order DNCB Kit Contact Us